Abdominal Oncology Ward, Division of Medical Oncology, Cancer Center, State Key Laboratory of Biological Therapy, West China Hospital, Sichuan University, Chengdu, China.
Abdominal Oncology Ward, Division of Radiation Oncology, Cancer Center, State Key Laboratory of Biological Therapy, West China Hospital, Sichuan University, Chengdu, China.
Front Immunol. 2023 Feb 8;14:1127071. doi: 10.3389/fimmu.2023.1127071. eCollection 2023.
Immune checkpoint inhibitors (ICIs) in the form of anti-CTLA-4 and anti-PD-1/PD-L1 have become the frontier of cancer treatment and successfully prolonged the survival of patients with advanced non-small cell lung cancer (NSCLC). But the efficacy varies among different patient population, and many patients succumb to disease progression after an initial response to ICIs. Current research highlights the heterogeneity of resistance mechanisms and the critical role of tumor microenvironment (TME) in ICIs resistance. In this review, we discussed the mechanisms of ICIs resistance in NSCLC, and proposed strategies to overcome resistance.
免疫检查点抑制剂（ICIs）以抗 CTLA-4 和抗 PD-1/PD-L1 的形式成为癌症治疗的前沿，成功延长了晚期非小细胞肺癌（NSCLC）患者的生存期。但在不同患者群体中的疗效存在差异，许多患者在对 ICI 初始反应后仍因疾病进展而死亡。目前的研究强调了耐药机制的异质性和肿瘤微环境（TME）在 ICI 耐药中的关键作用。在这篇综述中，我们讨论了 NSCLC 中 ICI 耐药的机制，并提出了克服耐药的策略。
